Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective follow-up study of subcutaneous tocilizumab in rheumatoid arthritis
NL-OMON41073Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Jan van Breemen Institute. Primary endpoints: DAS28 response and RAPID-3/MDHAQ-2 effect. Started Jun 2015; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41073.